{
  "id": "60266cf31cb411341a0000c4",
  "type": "summary",
  "question": "What is the mechanism of action of satralizumab?",
  "ideal_answer": "Satralizumab is a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody that has been approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD).",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32797372",
    "http://www.ncbi.nlm.nih.gov/pubmed/33011853",
    "http://www.ncbi.nlm.nih.gov/pubmed/32228250",
    "http://www.ncbi.nlm.nih.gov/pubmed/32333898",
    "http://www.ncbi.nlm.nih.gov/pubmed/32306778",
    "http://www.ncbi.nlm.nih.gov/pubmed/31774956",
    "http://www.ncbi.nlm.nih.gov/pubmed/32731771",
    "http://www.ncbi.nlm.nih.gov/pubmed/32348222",
    "http://www.ncbi.nlm.nih.gov/pubmed/33301078",
    "http://www.ncbi.nlm.nih.gov/pubmed/30623348",
    "http://www.ncbi.nlm.nih.gov/pubmed/32304439",
    "http://www.ncbi.nlm.nih.gov/pubmed/33059216",
    "http://www.ncbi.nlm.nih.gov/pubmed/33167776"
  ],
  "snippets": [
    {
      "text": "Satralizumab (Enspryng\u00ae), a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, has been developed by Chugai Pharmaceutical and Roche for the treatment of neuromyelitis optica spectrum disorder (NMOSD). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32797372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Monoclonal antibodies targeting terminal complement (eculizumab), CD19 (inebilizumab), and the interleukin-6 receptor (satralizumab) have demonstrated efficacy in NMOSD attack prevention in recent phase 3 trials and have gained subsequent regulatory approval in the USA and other countries. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33301078",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two of these, the antiinterleukin 6 (IL-6) agents tocilizumab and satralizumab, have been studied in active NMOSD.O",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32348222",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The interleukin-6 receptor inhibitor satralizumab and anti-CD19 antibody inebilizumab have published positive phase III trial results and await approval in the near future.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32228250",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Clinical trials of AQP4-IgG-positive NMOSD patients showed success with eculizumab (preventing cleavage of complement factor C5, thereby blocking formation of chemotactic C5a and membrane attack complex C9neo), inebilizumab (depleting CD19\u200a+\u200aB cells), and satralizumab (anti-IL-6R blocking IL-6 actions).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32304439",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Introduction: Recent research has shown that IL-6 receptor (IL-6\u00a0R) inhibitors like tocilizumab and satralizumab are effective in reducing the relapse rate in patients with NMOSD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32306778",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SION: In NMOSD patients with antibodies against aquaporin 4, monoclonal antibodies that deplete B cells (rituximab and inebilizumab) or interfere with interleukin 6 signaling (tocilizumab and satralizumab) or complement activation (eculizumab) have superior efficacy compared to placebo. Tocil",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33011853",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " now have three agents indicated for the treatment of NMO including (eculizumab [Soliris\u00ae]), an anti-C5 complement inhibitor, satralizumab (ENSRYNG\u00ae), a monoclonal antibody against the IL-6 receptor (IL-6R) that blocks B cell antibody production and inebilizumab (Uplinza\u00ae), a monoclonal antibody that binds to the B-cell surface antigen CD19 with subsequent B and plasmablast cell lymphocytolysis with decreasing antibody production. A",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33059216",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Satralizumab is a humanized monoclonal antibody targeting the interleukin-6 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31774956",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND: Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32333898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Satralizumab, a humanised monoclonal antibody targeting the interleukin-6 receptor, reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when added to immunosuppressant therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32333898",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Satralizumab, a humanized monoclonal antibody, was designed to treat NMOSD by targeting the IL-6 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33167776",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Satralizumab (Enspryng\u00ae), a humanized anti-interleukin-6 (IL-6) receptor monoclonal recycling antibody, has been developed by Chugai Pharmaceutical and Roche for the treatment of neuromyelitis optica spectrum disorder (NMOSD).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32797372",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "dicated agents for NMOSD. We now have three agents indicated for the treatment of NMO including (eculizumab [Soliris\u00ae]), an anti-C5 complement inhibitor, satralizumab (ENSRYNG\u00ae), a monoclonal antibody against the IL-6 receptor (IL-6R) that blocks B cell antibody production and inebilizumab (Uplinza\u00ae), a monoclonal antibody that binds to the B-cell surface antigen CD19 with subsequent B and plasmablast cell lymphocytolysis with decre",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33059216",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "After the considerable progress on diagnosis, we are now close to class I evidence for a therapeutic effect of several drugs in NMO spectrum disorders, most notably with the anti-interleukin-6 receptor antibody (satralizumab) and anti-complement-5 antibody (eculizumab).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30623348",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Some such drugs are the 2019-approved complement inhibitor eculizumab, other compounds in late development include its modified successor ravulizumab, IL-6 receptor antibody satralizumab, CD19 targeting antibody inebilizumab and the TACI-Fc fusion protein telitacicept.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32731771",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}